Literature DB >> 21375803

Comparison of canine umbilical cord blood-derived mesenchymal stem cell transplantation times: involvement of astrogliosis, inflammation, intracellular actin cytoskeleton pathways, and neurotrophin-3.

Sung-Su Park1, Ye-Eun Byeon, Hak-Hyun Ryu, Byung-Jae Kang, YongSun Kim, Wan-Hee Kim, Kyung-Sun Kang, Ho-Jae Han, Oh-Kyeong Kweon.   

Abstract

Canine mesenchymal stem cells (cMSCs) derived from umbilical cord blood represent a potentially useful source of stem cells for therapy. The aim of this study was to compare the effects of different transplantation times of cMSCs after spinal cord injury (SCI). A total of 21 dogs were subjected to SCI by balloon-induced compression of the first lumbar vertebrae for 12 h. Of the 21 dogs, 12 were divided into four groups of three according to the time of stem cell (1 × 10(6)) transplantation at the injury site: control no treatment, 12 h, 1 week, and 2 weeks. The remaining 9 animals were negative harvest (HA) time controls for each treatment group (n = 3). Olby and Tarlov scores were used to evaluate functional recovery of the hindlimbs. Markers for neuronal regeneration (Tuj-1, nestin, MAP2, and NF-M), astrogliosis (GALC, GFAP, and pSTAT3), signal molecules for actin cytoskeleton (RhoA, Cdc42, and Rac1), inflammation (COX-2), and neurotrophins (NT-3) were evaluated by Western blot analysis. Scores of the 1-week transplantation group showed significant improvement compared to controls. Hematoxylin and eosin (H&E) staining revealed less fibrosis at the injury site in the 1-week transplantation group compared to other groups and immunohistochemistry showed increased expression of neuronal markers. Furthermore, in both 1-week and 2-week transplantation groups, Tuj-1, nestin, MAP2, NF-M, NT-3, and GFAP increased, but pSTAT3, GALC, and COX2 decreased. RhoA decreased and Rac1 and Cdc42 increased in the 1-week transplantation group. In conclusion, transplantation of cMSCs 1 week after SCI was more effective in improving clinical signs and neuronal regeneration and reducing fibrosis formation compared to the other transplantation times evaluated. Subsequently, these data may contribute to the optimization of timing for MSC transplantation used as a therapeutic modality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21375803     DOI: 10.3727/096368911X566163

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  25 in total

1.  Canine epidermal neural crest stem cells: characterization and potential as therapy candidate for a large animal model of spinal cord injury.

Authors:  Barbara Gericota; Joseph S Anderson; Gaela Mitchell; Dori L Borjesson; Beverly K Sturges; Jan A Nolta; Maya Sieber-Blum
Journal:  Stem Cells Transl Med       Date:  2014-01-17       Impact factor: 6.940

Review 2.  Translating stem cell therapies: the role of companion animals in regenerative medicine.

Authors:  Susan W Volk; Christine Theoret
Journal:  Wound Repair Regen       Date:  2013-04-29       Impact factor: 3.617

Review 3.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

4.  The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells.

Authors:  Ya-Pei Chang; Hsuan-Ping Hong; Yen-Hua Lee; I-Hsuan Liu
Journal:  J Vet Med Sci       Date:  2014-11-12       Impact factor: 1.267

5.  Factors affecting directional migration of bone marrow mesenchymal stem cells to the injured spinal cord.

Authors:  Peng Xia; Su Pan; Jieping Cheng; Maoguang Yang; Zhiping Qi; Tingting Hou; Xiaoyu Yang
Journal:  Neural Regen Res       Date:  2014-09-15       Impact factor: 5.135

Review 6.  Cell therapy and delivery strategies for spinal cord injury.

Authors:  Bruna Dos S Ramalho; Fernanda M de Almeida; Ana M B Martinez
Journal:  Histol Histopathol       Date:  2021-06-10       Impact factor: 2.303

Review 7.  Stem cells in canine spinal cord injury--promise for regenerative therapy in a large animal model of human disease.

Authors:  Barbara G McMahill; Dori L Borjesson; Maya Sieber-Blum; Jan A Nolta; Beverly K Sturges
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

Review 8.  Cell transplantation for spinal cord injury: a systematic review.

Authors:  Jun Li; Guilherme Lepski
Journal:  Biomed Res Int       Date:  2013-01-15       Impact factor: 3.411

9.  Neuronal cell differentiation of mesenchymal stem cells originating from canine amniotic fluid.

Authors:  Eun Young Kim; Kyung-Bon Lee; Jung Yu; Ji Hye Lee; Keun Jung Kim; Kil-Woo Han; Kang-Sun Park; Dong-Soo Lee; Min Kyu Kim
Journal:  Hum Cell       Date:  2013-10-29       Impact factor: 4.174

10.  Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury.

Authors:  Hongbin Cheng; Xuebin Liu; Rongrong Hua; Guanghui Dai; Xiaodong Wang; Jianhua Gao; Yihua An
Journal:  J Transl Med       Date:  2014-09-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.